SCHEDULE: Leon Cooperman Discloses 6% Stake in DiaMedica Therapeutics

Veteran investor Leon Cooperman has revealed a 6% passive ownership stake in DiaMedica Therapeutics Inc., holding over 3.1 million common shares.

Summary

• Leon G. Cooperman has filed a Schedule 13G, disclosing beneficial ownership in DiaMedica Therapeutics Inc.
• Mr. Cooperman beneficially owns 3,110,220 Voting Common Shares, which constitutes 6.0% of the company's total outstanding shares.
• This ownership is composed of 2,450,000 Common Shares held directly by Mr. Cooperman and 660,220 Common Shares held by The Leon and Toby Cooperman Foundation, where Mr. Cooperman serves as a trustee.
• The 6.0% ownership percentage is calculated based on 51,688,913 Common Shares outstanding as of August 8, 2025, as reported in DiaMedica's Quarterly Report on Form 10-Q filed on August 12, 2025.
• The securities were acquired and are held for investment purposes and not with the intent to change or influence the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a well-known investor like Leon Cooperman is generally viewed positively, as it can indicate confidence in the company's value and future. The passive nature suggests no immediate intent to disrupt management, which is also often seen favorably.

Positives

• A prominent investor, Leon G. Cooperman, has taken a significant 6.0% stake in DiaMedica Therapeutics, which may signal confidence in the company's long-term value and prospects.
• The investment is passive, indicating that Mr. Cooperman believes in the current management and strategic direction without intending to influence control.

Industry Context

The disclosure of a significant stake by a prominent investor like Leon Cooperman can sometimes draw attention to a company within its industry, potentially signaling a perceived undervaluation or strong future prospects, especially in the biotechnology or pharmaceutical sector where long-term development cycles are common. Such an investment can be seen as a vote of confidence, potentially attracting further investor interest.

Related Party Transactions

• Leon G. Cooperman's beneficial ownership includes shares held by The Leon and Toby Cooperman Foundation, a charitable trust where he is one of the trustees. This represents a related party holding within his disclosed aggregate ownership.

Stakeholder Impact

• Shareholders may view the investment by a prominent investor as a positive signal, potentially increasing confidence and attracting further investment.
• Management may perceive the passive nature of the investment as an endorsement of their current strategy, allowing them to continue executing their plans without immediate pressure for strategic changes.

Key Dates

Recommendation

While the disclosure of a significant stake by a respected investor like Leon Cooperman is a positive signal, this filing alone does not provide enough fundamental information about DiaMedica Therapeutics' operations, financial performance, or strategic developments to warrant a 'buy' or 'strong buy' recommendation. It primarily indicates a vote of confidence from a notable investor. A 'hold' recommendation is appropriate, suggesting investors monitor the company's performance and future disclosures for more comprehensive insights before making further investment decisions.

Keywords

DiaMedica Therapeutics, DMAC, Leon Cooperman, Schedule 13G, beneficial ownership, institutional investor, common shares, biotechnology, pharmaceuticals